Effectiveness of a Hypertension-focused Digital AppLication in a CommunitY Sample: Randomized CONtrolled Trial (HALCYON”)

Phase 4

• Conditions: I10-I15; Hypertensive diseases

• Registration Number: DRKS00025871
• Lead Sponsor: GAIA AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-05
• Study Completion: 2022-07-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting stopped after recruiting started
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

•at least Stage 1 hypertension (= 135/85 mmHg und < 175/105 mmHg, home-based)
•no initial prescription or change of dosage, composition or agent of drug therapy (no new agent) of antihypertensive drug therapy in the past 6 weeks
• Sufficient understanding of the German language
• Consent to participation

Exclusion Criteria

•more than 3 antihypertensive agents (> triple-combination)
•secondary hypertension (i.e., thyroid disease, kidney disease)
•pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Systolic blood pressure (in mmHg) after 3 months of intervention

Secondary Outcome Measures

Name	Time	Method
- Responder Rate (calculated based on blood pressure values)<br>- Pulse Pressure (calculated based on blood pressure values)<br>- Quality of life (assessed by WHOQOL-BREF)<br>- Medication adherence (assessed by the Rief Adherence Index, RAI)<br>- Ability to work (assessed by the Work and Social Assessment Scale, WSAS)